Can I take atenolol if I also use a levalbuterol inhaler?

These drugs have opposing effects on the airways. Atenolol can reduce the effectiveness of levalbuterol and may worsen breathing in people with asthma or COPD. Discuss all options with your doctor before combining them.

Why would a doctor prescribe both a beta-blocker and a beta-agonist?

Sometimes both heart and lung conditions require treatment simultaneously. In such cases, a cardioselective beta-blocker like atenolol may be used at the lowest effective dose with careful monitoring.

Is atenolol safer than propranolol in asthma patients?

Yes. Atenolol is more cardioselective (beta-1 preferring) than propranolol, which blocks both beta-1 and beta-2 receptors. Cardioselective agents cause less bronchospasm, though they are not entirely safe in severe asthma.

What symptoms suggest this combination is causing a problem?

Increased wheezing, shortness of breath, chest tightness, or needing your rescue inhaler more often may indicate that atenolol is blocking the effect of levalbuterol. Report these symptoms to your provider immediately.

Atenolol & Levalbuterol Interaction

Moderate

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Using this site does not create a doctor-patient relationship.

Drug information changes as the FDA updates labeling, and we cannot guarantee it is complete or current. Verify critical details with your pharmacist or physician.

Emergencies: If you think you may have a medical emergency, call 911 immediately. For a suspected overdose, call Poison Control at 1-800-222-1222. Report side effects to the FDA MedWatch program at fda.gov/medwatch or 1-800-FDA-1088.

See our Terms of Use and Editorial Policy.

Learn more about Atenolol →Learn more about Levalbuterol →

Overview

Atenolol (a cardioselective beta-1 adrenergic blocker) and levalbuterol (a selective beta-2 agonist bronchodilator) have pharmacodynamically antagonistic mechanisms. Beta-blockers can blunt the bronchodilatory response to beta-2 agonists and may precipitate bronchospasm in patients with reactive airway disease. This combination warrants careful clinical evaluation.

How does this interaction occur?

Levalbuterol activates beta-2 adrenergic receptors in bronchial smooth muscle, causing bronchodilation and relief of bronchoconstriction. Atenolol blocks beta-1 adrenergic receptors (cardiac selective), but at higher doses can also block beta-2 receptors. Beta-2 blockade antagonizes levalbuterol bronchodilation and can cause bronchoconstriction. Conversely, levalbuterol can partially overcome beta-blockade and may cause reflex tachycardia or hypertension if beta-2-mediated vasodilation is blocked.

Clinical significance

In patients with both reactive airway disease (asthma or COPD) and cardiovascular disease (hypertension, heart failure, coronary artery disease) requiring a beta-blocker, this combination requires careful risk-benefit assessment. The cardioselectivity of atenolol reduces but does not eliminate the risk of bronchospasm. Clinical studies have shown that cardioselective beta-blockers are safer than non-selective agents in mild-moderate asthma, but are not risk-free.

Management recommendations

If beta-blocker therapy is essential in a patient using levalbuterol, use the most cardioselective agent (atenolol, metoprolol, bisoprolol) at the lowest effective dose. Monitor closely for increased shortness of breath, wheezing, or decreased levalbuterol efficacy. Consider an alternative antihypertensive (e.g., amlodipine, ACE inhibitor) if beta-blocker can be avoided. Avoid non-selective beta-blockers (e.g., propranolol) in these patients.

What to monitor

Pulmonary function (peak flow, spirometry) at initiation and periodically. Blood pressure and heart rate. Symptom assessment for increased dyspnea or wheezing. Rescue inhaler use frequency as indicator of bronchospasm risk.

Alternative options

For cardiovascular indications, consider ACE inhibitors, ARBs, or calcium channel blockers as alternatives to atenolol where appropriate. For airway disease, if reactive airway disease is significant, avoid beta-blockers when possible. Consult pulmonology and cardiology for complex co-management.

Frequently asked questions

References

[Regulatory] Atenolol FDA Prescribing Information https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/018240s040lbl.pdf Accessed 2026-03-01.
[Regulatory] Levalbuterol (Xopenex) FDA Prescribing Information https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021212s018lbl.pdf Accessed 2026-03-01.
[Regulatory] Salpeter SR et al. Cardioselective beta-blockers in patients with reactive airway disease. Ann Intern Med 2002. https://pubmed.ncbi.nlm.nih.gov/12215136/ Accessed 2026-03-01.

Written and fact-checked by PrescriptionDrugs.org Editorial Team

Last updated: March 1, 2026